Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Andrés Romo Collado"'
Autor:
Angeles Fernandez, Juan Luis Steegmann, Andrés Romo Collado, Isabel Mata, José Tallón, María José Sánchez, Ana Iglesias Pérez, Concepción Ruiz, Ana Sebrango, Jose Luis Lopez Lorenzo, Maria del Carmen García Garay, Alejandra Martínez-Trillos, Esperanza Romero, Fernando Ortega, Maria Luisa Martin Mateos, Beatriz Cuevas, Angeles Portero, José María Guinea, Valentín García-Gutiérrez, Begoña Maestro, Sandra Valencia, Pilar Giraldo, Natalia de las Heras, Sabela Bobillo, Guillermo Deben, Concepción Boqué, Alberto Alvarez-Larrán, Guiomar Bautista
Publikováno v:
American Journal of Hematology. 90:429-433
The role of bosutinib as rescue treatment of Philadelphia chromosome-positive chronic myeloid leukemia (CML) patients after failing three previous tyrosine kinase inhibitors (TKIs) is currently unknown. We report here the largest series (to our knowl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e575b2dea2d4f8bde015d131c52b5b9d
https://doi.org/10.1002/ajh.23973
https://doi.org/10.1002/ajh.23973
Autor:
Valentín, García-Gutiérrez, Alejandra, Martinez-Trillos, Jose Luis, Lopez Lorenzo, Guiomar, Bautista, Maria Luisa, Martin Mateos, Alberto, Alvarez-Larrán, Ana, Iglesias Pérez, Andrés, Romo Collado, Angeles, Fernandez, Angeles, Portero, Beatriz, Cuevas, Concepción, Ruiz, Esperanza, Romero, Fernando, Ortega, Isabel, Mata, José, Tallón, Maria Del Carmen, García Garay, María José, Ramirez Sánchez, Natalia, de Las Heras, Pilar, Giraldo, Sabela, Bobillo, José María, Guinea, Guillermo, Deben, Sandra, Valencia, Ana, Sebrango, Concepción, Boqué, Begoña, Maestro, Juan Luis, Steegmann
Publikováno v:
American journal of hematology. 90(5)
The role of bosutinib as rescue treatment of Philadelphia chromosome-positive chronic myeloid leukemia (CML) patients after failing three previous tyrosine kinase inhibitors (TKIs) is currently unknown. We report here the largest series (to our knowl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::b6cf05ee1b2903a22595edfe37a5f9ca
https://pubmed.ncbi.nlm.nih.gov/25683327
https://pubmed.ncbi.nlm.nih.gov/25683327
Autor:
Maria del Carmen García Garay, Concepción Ruiz, Alejandra Martinez-Trillo, Andrés Romo Collado, Ana Iglesias Pérez, María José Sánchez, Isabel Mata, Jose Luis Lopez Lorenzo, Guiomar Bautista, Juan Luis Steegmann, Beatriz Cuevas, Ana Sebrango, Alberto Alvarez, Guillermo Deben, Fernando Ortega, Esperanza Romero, Concepción Boqué, Maria Luisa Martin Mateos, Sandra Valencia, Angeles Fernandez, Angeles Portero, Pilar Giraldo, Sabela Bobillo, Natalia de las Heras, José Tallón, José María Guinea, Valentín García-Gutiérrez, Begoña Maestro
Publikováno v:
Blood. 124:5523-5523
Second-generation TKIs have demonstrated efficacy and an acceptable tolerability in patients (pts) with chronic myeloid leukemia (CML); however, new data from so called “off target” side effects have been published. For example, serious concerns
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::51e4792cc83943dc85b8376385f37196
https://doi.org/10.1182/blood.v124.21.5523.5523
https://doi.org/10.1182/blood.v124.21.5523.5523